KTTA Overview

Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases. The Company is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 (MEK 1/2) for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and a number of oncology indications, among others. Its remaining two programs, PAS-001 and PAS-003, are in the earlier stages of development and are based on novel targets for the treatment of CNS disorders that it believes address limitations in the treatment paradigm of the indications it plans to address, which are amyotrophic lateral sclerosis (ALS) for its PAS-003 program, and schizophrenia for its PAS-001 program.

Wall Street analysts forecast KTTA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KTTA is3.00 USD with a low forecast of 3.00 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Pasithea Therapeutics Corp revenue for the last quarter amounts to 0.00 USD, decreased

Pasithea Therapeutics Corp. EPS for the last quarter amounts to -0.79 USD, decreased -68.77

Pasithea Therapeutics Corp (KTTA) has 5 emplpoyees as of April 21 2026.

Today KTTA has the market capitalization of 17.89M USD.